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Mucinous cystic neoplasm (MCN) occurs predominantly
in women (>95%) with a mean age of approximately
45 years and most commonly is located in the pancreatic
body or tail. The mass is lined by mucin-producing
columnar epithelium with a fibrous ovarian-type stroma.
The epithelial lining can contain various degrees of aty-
pia, ranging from adenoma to invasive carcinoma. The
CT and MR appearance is that of a thick walled cystic
mass with septa and/or mural nodules. The contour of
the mass is smooth, and the wall or septa may contain
calcification. Endoscopic ultrasound with fine needle
aspiration of the cyst fluid to assess CEA level may be
helpful in distinguishing MCN from serous cystadenoma.
CEA <5 ng/mL favors serous cystadenoma, whereas CEA
>192 ng/mL favors MCN, with an accuracy of approxi-
mately 80% [1]. The overall risk of malignancy in one
series was 17.5%, and all malignant tumors were either
>4 cm or contained mural nodules [2]. Treatment of
MCN is surgical resection, and patients without extra-
capsular or diffuse intracapsular infiltration have an
excellent prognosis [2].
Serous cystadenoma (SCA) also occurs predominantly
in women (approximately 75%), but the mean age is
older (mid 50s to early 60s). It is lined by glycogen-rich
cuboidal epithelium and is considered a benign neo-
plasm, although rare cases of malignant SCA have been
reported. The typical appearance is that of a lobulated
mass consisting of numerous tiny cysts which give it a
honeycomb appearance. Larger lesions may contain a
central stellate scar and calcifications. Oligocystic or
macrocystic SCA is an uncommon variant comprised of
a small number of larger cysts. Distinction between
macrocystic SCA and MCN can be made based on the
lobulated contour of SCA, its multiple clustered cyst
configuration and homogeneity of each locule on T1
weighted MR images [3]. Surgical resection generally is
reserved for symptomatic patients, although some
authors recommend periodic imaging to assess the rate
of growth, with consideration given to surgical resection
of lesions with doubling time of <6 years [4].
Solid pseudopapillary neoplasm (SPN) is a rare low-
grade malignancy that predominantly affects younger
women (>80%), with a median age 30-38 years [5,6]. It is
not a true cystic neoplasm in that the cystic component
lacks an epithelial lining. Rather, the cystic component
represents necrotic degeneration of the mass, with various
amounts of internal blood and debris. SPN appears as a
well-circumscribed round or oval thick-walled mass with
solid and cystic components, but it can appear completely
solid or completely cystic. CT demonstrates calcification
in nearly half of SPNs [6]. MR often demonstrates a thick
T2 hypointense or enhancing rim and internal blood
products. Treatment is surgical resection, and the prog-
nosis is excellent, with metastases developing in <5% of
patients [6].
Cystic neuroendocrine neoplasm of the pancreas most
commonly occurs in patients with multiple endocrine neo-
plasia type I and usually is nonfunctional [7]. It generally
appears as a cystic mass with an enhancing rim and may
contain septa or a solid component. Treatment usually is
surgical resection, although observation may be a viable
alternative approach [8].
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